P450 oxidoreductase: Genetic polymorphisms and implications for drug metabolism and toxicity

Steven Hart, Xiao Bo Zhong

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Background: Cytochrome P450 oxidoreductase (POR) is the only electron donor for all microsomal cytochrome P450 monooxygenases (CYP), some of which are phase I drug-metabolizing enzymes, responsible for oxidation of more than 80% of drugs. Objectives: To provide a more thorough understanding of the genetic factors influencing drug metabolism, we address the role of genetic polymorphisms in the POR gene, and their implications for drug metabolism and cytotoxicity. Methods: The scope of this review is intended to cover polymorphisms currently identified in the POR gene, assess their functional significance on POR activity, and address their impact on CYP-mediated drug metabolism. POR is also responsible for directly metabolizing several anticancer prodrugs via a 1-electron reduction reaction, so the effect of POR polymorphisms on the direct bioactivation of drugs is also considered. Results/conclusion: POR is a polymorphic enzyme that can affect CYP-mediated drug metabolism as well as direct bioactivation of prodrugs. Genetic polymorphisms in the POR gene may help to explain altered drug-metabolizing phenotypes.

Original languageEnglish (US)
Pages (from-to)439-452
Number of pages14
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume4
Issue number4
DOIs
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Genetic Polymorphisms
Drug-Related Side Effects and Adverse Reactions
Polymorphism
Metabolism
Toxicity
Oxidoreductases
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Mixed Function Oxygenases
Genes
Prodrugs
Electrons
Enzymes
Cytotoxicity
Phenotype
Oxidation

Keywords

  • Cytochrome P450 oxidoreductase
  • Drug metabolism
  • Genetic polymorphism
  • Pharmacogenetics
  • POR
  • Toxicity

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

P450 oxidoreductase : Genetic polymorphisms and implications for drug metabolism and toxicity. / Hart, Steven; Zhong, Xiao Bo.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, No. 4, 01.04.2008, p. 439-452.

Research output: Contribution to journalReview article

@article{9ba092e183b14e07b1859021ae3a0e71,
title = "P450 oxidoreductase: Genetic polymorphisms and implications for drug metabolism and toxicity",
abstract = "Background: Cytochrome P450 oxidoreductase (POR) is the only electron donor for all microsomal cytochrome P450 monooxygenases (CYP), some of which are phase I drug-metabolizing enzymes, responsible for oxidation of more than 80{\%} of drugs. Objectives: To provide a more thorough understanding of the genetic factors influencing drug metabolism, we address the role of genetic polymorphisms in the POR gene, and their implications for drug metabolism and cytotoxicity. Methods: The scope of this review is intended to cover polymorphisms currently identified in the POR gene, assess their functional significance on POR activity, and address their impact on CYP-mediated drug metabolism. POR is also responsible for directly metabolizing several anticancer prodrugs via a 1-electron reduction reaction, so the effect of POR polymorphisms on the direct bioactivation of drugs is also considered. Results/conclusion: POR is a polymorphic enzyme that can affect CYP-mediated drug metabolism as well as direct bioactivation of prodrugs. Genetic polymorphisms in the POR gene may help to explain altered drug-metabolizing phenotypes.",
keywords = "Cytochrome P450 oxidoreductase, Drug metabolism, Genetic polymorphism, Pharmacogenetics, POR, Toxicity",
author = "Steven Hart and Zhong, {Xiao Bo}",
year = "2008",
month = "4",
day = "1",
doi = "10.1517/17425255.4.4.439",
language = "English (US)",
volume = "4",
pages = "439--452",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - P450 oxidoreductase

T2 - Genetic polymorphisms and implications for drug metabolism and toxicity

AU - Hart, Steven

AU - Zhong, Xiao Bo

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Background: Cytochrome P450 oxidoreductase (POR) is the only electron donor for all microsomal cytochrome P450 monooxygenases (CYP), some of which are phase I drug-metabolizing enzymes, responsible for oxidation of more than 80% of drugs. Objectives: To provide a more thorough understanding of the genetic factors influencing drug metabolism, we address the role of genetic polymorphisms in the POR gene, and their implications for drug metabolism and cytotoxicity. Methods: The scope of this review is intended to cover polymorphisms currently identified in the POR gene, assess their functional significance on POR activity, and address their impact on CYP-mediated drug metabolism. POR is also responsible for directly metabolizing several anticancer prodrugs via a 1-electron reduction reaction, so the effect of POR polymorphisms on the direct bioactivation of drugs is also considered. Results/conclusion: POR is a polymorphic enzyme that can affect CYP-mediated drug metabolism as well as direct bioactivation of prodrugs. Genetic polymorphisms in the POR gene may help to explain altered drug-metabolizing phenotypes.

AB - Background: Cytochrome P450 oxidoreductase (POR) is the only electron donor for all microsomal cytochrome P450 monooxygenases (CYP), some of which are phase I drug-metabolizing enzymes, responsible for oxidation of more than 80% of drugs. Objectives: To provide a more thorough understanding of the genetic factors influencing drug metabolism, we address the role of genetic polymorphisms in the POR gene, and their implications for drug metabolism and cytotoxicity. Methods: The scope of this review is intended to cover polymorphisms currently identified in the POR gene, assess their functional significance on POR activity, and address their impact on CYP-mediated drug metabolism. POR is also responsible for directly metabolizing several anticancer prodrugs via a 1-electron reduction reaction, so the effect of POR polymorphisms on the direct bioactivation of drugs is also considered. Results/conclusion: POR is a polymorphic enzyme that can affect CYP-mediated drug metabolism as well as direct bioactivation of prodrugs. Genetic polymorphisms in the POR gene may help to explain altered drug-metabolizing phenotypes.

KW - Cytochrome P450 oxidoreductase

KW - Drug metabolism

KW - Genetic polymorphism

KW - Pharmacogenetics

KW - POR

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=44349094918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349094918&partnerID=8YFLogxK

U2 - 10.1517/17425255.4.4.439

DO - 10.1517/17425255.4.4.439

M3 - Review article

C2 - 18433346

AN - SCOPUS:44349094918

VL - 4

SP - 439

EP - 452

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 4

ER -